Hims & Hers is stopping its sales of an alternative to blockbuster weight-loss drugs Wegovy and Ozempic. That follows the U.S. Food and Drug Administration

The telehealth company has been selling a copycat version of a popular obesity drug during the recent shortage.

Key Takeaways Hims & Hers Health shares swooned after the Food & Drug Administration said the active ingredient in Ozempic and Wegovy is no longer in short supply.The company makes compounded versions of weight-loss drugs under an FDA rule that applies when the originals are difficult to obtain.